SignalXSignalX

OCUL OCULAR THERAPEUTIX, INC

FY2025 10-K
Filed: Feb 5, 2026
Health Care
Pharmaceutical PreparationsSEC EDGAR
OCULAR THERAPEUTIX, INC Overview

OCULAR THERAPEUTIX, INC (OCUL) filed its fiscal year 2025 10-K annual report with the SEC on Feb 5, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.

AI Filing Analysis
FY2025 10-K

Business Overview

  • • Core business: Integrated biopharmaceutical company developing ELUTYX hydrogel-based ocular drug delivery platform for retina diseases
  • • New emphasis on AXPAXLI (OTX-TKI), a Phase 3 axitinib intravitreal hydrogel implant targeting wet AMD and diabetic retinal disease with registrational trials SOL and HELIOS
+3 more insights

Management Discussion & Analysis

  • • Revenue $51.9M in 2025 vs $63.7M in 2024 and $58.4M in 2023, declining due to decreased DEXTENZA sales
  • • Net loss widened to $265.9M in 2025 from $193.5M in 2024 and $80.7M in 2023; operating expenses $322.0M in 2025
+3 more insights

Risk Factors

  • • Regulatory risk: FDA may require additional trials delaying AXPAXLI approval for wet AMD and diabetic retinal disease
  • • Macroeconomic exposure: $82.5M debt under Barings Credit Facility requires minimum liquidity $20M, royalty fee 3.5% of DEXTENZA sales
+3 more insights

Get deeper insights on OCULAR THERAPEUTIX, INC

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.

Try Pro free for 1 month!

Enter SX-8KKYTN at checkout

Limited spots available